Osteoporosis is a skeletal disorder characterised by reduced bone strength and increased susceptibility to fragility fractures. Bone is living tissue that undergoes continuous remodelling, with old bone removed by osteoclasts and new bone formed by osteoblasts. Osteoporosis develops when bone loss or inadequate bone formation reduces the structural strength of the skeleton beyond normal age-related changes. Bone density is an important component of strength, but bone quality, architecture, turnover and the presence of previous fractures also influence fracture risk.
Common fracture sites include the hip, vertebrae and wrist, although any bone can fracture. Osteoporosis is frequently silent until a fracture occurs, which makes prevention and risk assessment particularly important. NHS guidance distinguishes Osteoporosis from osteopenia, in which bone density is reduced but does not meet the usual threshold for osteoporosis.
Peak bone mass is generally achieved by early adulthood, after which bone remodelling gradually produces a net loss in many people. Ageing, hormonal changes and other factors can accelerate this process. Oestrogen has a major role in restraining bone resorption, which explains the accelerated bone loss that commonly occurs around and after Menopause. However, Osteoporosis is not exclusively a postmenopausal condition.
Men, younger women and children can develop it because of genetic disorders, endocrine disease, malabsorption, chronic inflammatory conditions, prolonged immobilisation, nutritional problems or medication exposure. Long-term or high-dose glucocorticoid therapy is a particularly important secondary cause. Risk therefore reflects the interaction between peak bone mass, subsequent bone loss and factors that increase the likelihood or consequences of falls.
Osteoporosis is usually assessed through bone mineral density measurement, most commonly with dual-energy X-ray absorptiometry, or DEXA. The scan uses low-dose X-rays to estimate bone mineral density at clinically relevant skeletal sites. A T-score compares bone density with that of a healthy young reference population and is used diagnostically in many postmenopausal women and older men, while Z-scores compare with age-matched populations and have different applications in younger people.
Fracture risk cannot be inferred from bone density alone, so clinical risk factors and, where appropriate, tools such as FRAX or QFracture are used to estimate future fracture probability. A person can sustain a fragility fracture without having a bone-density result that independently meets the densitometric definition of osteoporosis.
Fragility fractures are the central clinical consequence of Osteoporosis. Vertebral fractures can occur after relatively minor forces and may cause acute or chronic back pain, loss of height and progressive spinal curvature. Hip fractures can cause major loss of independence and are associated with substantial morbidity and mortality in older adults. Wrist and other fractures can also impair function. Repeated vertebral fractures can further alter spinal mechanics and increase subsequent fracture risk.
Importantly, a first fragility fracture is itself a strong predictor of future fractures, so fracture prevention remains important even when symptoms from the original injury have resolved. Falls are a major immediate mechanism for many fractures, meaning prevention involves both skeletal strength and balance, strength and environmental safety.
Prevention and treatment of Osteoporosis involve reducing modifiable risk factors and, when indicated, using bone-active medication. Adequate calcium and vitamin D, regular weight-bearing and resistance exercise, smoking cessation and moderation of alcohol intake support skeletal health. Medicines can reduce bone resorption or, in selected circumstances, stimulate bone formation. Bisphosphonates and other antiresorptive agents are commonly used according to individual fracture risk, while anabolic or bone-forming treatments may be considered for people at particularly high risk. Treatment selection depends on fracture history, bone density, kidney function, age, other diseases, medication interactions and individual circumstances. Medication is not normally prescribed solely because someone has mildly reduced bone density without considering overall fracture risk.
Osteoporosis has a particularly important relationship with Menopause and Postmenopause. The fall in ovarian oestrogen accelerates bone remodelling and can produce substantial loss of bone mineral density during the years surrounding and following menopause. HRT can reduce bone loss and osteoporosis risk in appropriate individuals, especially when menopause occurs early, although HRT is not automatically the preferred osteoporosis treatment for every person. Other antiresorptive and anabolic therapies may be more appropriate depending on fracture risk and medical circumstances. The connection also illustrates why osteoporosis prevention should begin before old age: achieving good peak bone mass and avoiding preventable bone loss can substantially influence skeletal reserve later in life.
Osteoporosis should be distinguished from osteoarthritis and from ordinary age-related bone loss. Osteoarthritis is primarily a disorder of joints involving cartilage, subchondral bone and other joint tissues, whereas Osteoporosis weakens the skeleton and predisposes to fractures without necessarily causing joint pain. Normal age-related reduction in bone density is not automatically Osteoporosis; diagnosis depends on the degree of bone loss, fracture history and overall clinical context. Osteopenia indicates lower-than-reference bone density that does not meet the densitometric threshold for osteoporosis and does not inevitably progress to osteoporosis. These distinctions are important because the symptoms, investigations, treatments and complications of the conditions differ substantially.
The significance of Osteoporosis extends beyond bone density because fractures can affect mobility, independence, employment, social participation and general health. WHO classifies osteoporosis among major musculoskeletal conditions and notes that these disorders contribute substantially to disability and rehabilitation needs worldwide. Prevention therefore includes maintaining muscle strength and balance as well as bone strength.
Secondary osteoporosis should also be considered when bone loss occurs unexpectedly or at a young age, because identifying an underlying endocrine, gastrointestinal, inflammatory or medication-related cause can change management. Osteoporosis is thus best understood as a disorder of skeletal strength and fracture risk rather than simply “thin bones”, and effective care combines risk assessment, diagnosis, prevention of falls and appropriately selected treatment.
